Monday, October 26, 2020
Home Tags MCRPC

Tag: mCRPC

Novel Bispecific Monoclonal Antibody Demonstrates Preclinical Promise Against STEAP1 Target in...

The novel immunotherapy AMG 509 has demonstrated promising preclinical activity in STEAP1-expressing prostate cancer cells. Results of the ongoing first-in-human study of AMG 509...

Onvansertib Combo Achieves Disease Control, Overcomes Abiraterone Resistance in mCRPC

The combination of onvansertib (PCM-075) plus abiraterone acetate (Zytiga) and prednisone achieved disease control in patients with metastatic castration-resistant prostate cancer who had initial...

Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial...

SAN DIEGO, Oct. 20, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need...

Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients...

NEW YORK--(BUSINESS WIRE)-- The Canadian Cancer Trials Group (CCTG) today announced the commencement of a new sub-study evaluating CFI-400945, an oral, first-in-class inhibitor of...

Sipuleucel-T boosts survival versus abiraterone or enzalutamide alone in real-world mCRPC...

Real-world data showed that use of the immunotherapy sipuleucel-T (Provenge) during any line of treatment in men with metastatic castration-resistant prostate cancer (mCRPC) improved...

Reserve PARP Inhibitors for mCRPC With BRCA Mutations

For men with metastatic castration-resistant prostate cancer (mCRPC), any new therapy that offers the chance of a higher...

Ipatasertib/abiraterone regimen delays progression in mCRPC with PTEN loss

The addition of the AKT inhibitor ipatasertib to abiraterone acetate (Zytiga) and prednisone delayed disease progression and induced superior antitumor activity in patients with...

Study of ZEN-3694 Plus Enzalutamide Demonstrates Possible Efficacy in Patients with...

A phase 1b/2a study of ZEN-3694 plus enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) demonstrated acceptable tolerability and potential efficacy of...

Pivotal rucaparib phase 3 mCRPC data published

The pivotal findings from the phase 3 TRITON2 trial, which led to the FDA approval of rucaparib (Rubraca) in BRCA-positive metastatic castration-resistant prostate cancer...
20,764FansLike
2,400FollowersFollow
16,600SubscribersSubscribe

EDITOR PICKS